Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • stockkarr stockkarr Dec 2, 2009 3:03 PM Flag

    R&D Day News/updates?

    Anyone? See that it is today, but haven't looked at any materials or anything. If anyone has any thoughts/comments - they are always appreciated by many, I know.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I sort of halfway listened to it while I was doing other stuff.

      Interesting that Dr. Scangos at lest tacitly acknowledged that a takeover was possible at any time.

      The 125 mg XL184 data set looks good, but numgers are too small to draw any definitive conclusions.

      • 1 Reply to erniewerner
      • Interesting - thank you both for sharing your thoughts.

        I wouldn't be surprised if they've received an initial offer from BMY - if you look on the negotiation history of MEDX, the first foray was probably a lowball offer. The wrinkle here is that the overall market situation was reversed.

        This is all guess work - but if there is no new partnership by EOY, strategic direction might be focused on a negotiated takeover. Either way - compelling reasons to accumulate.

    • I only caught the tail end of the call but scanned through the slides. There was some encouraging data on XL184 as we have recently seen plus a description of some their efforts/trials with XL184 now enrolling to explore other potential indications. There was also a significant amount of time dedicated to XL147 and XL765 combination trials.

      Additionally there was mention of some of their pre-clinical compounds that should garner (or already have) partnership interest IMO. I expect the practice of partnering these early with 0 or close to 0% development cost share in exchange for development milestones to continue for the next few years until they have real revenue to subsidize their R&D.

 
EXEL
3.08-0.02(-0.65%)Apr 24 4:00 PMEDT